Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High dose Lucentis for persistent PED in nAMD
NCT01189019Phase 2Terminated
- Sponsor
- Perceive Biotherapeutics
- Start
- Aug 2010
- Primary completion
- Mar 2013
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), retinal pigment epithelial detachment (PED), sponsored by Perceive Biotherapeutics. Started Aug 2010; status: terminated.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)retinal pigment epithelial detachment (PED)
Beyond the preview
Go deeper on NCT01189019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189019.